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Using in vivo-induced antigen technology (IVIAT), a modified immunoscreening technique that circumvents
the need for animal models, we directly identified immunogenic Escherichia coli O157:H7 (O157) proteins
expressed either specifically during human infection but not during growth under standard laboratory con-
ditions or at significantly higher levels in vivo than in vitro. IVIAT identified 223 O157 proteins expressed
during human infection, several of which were unique to this study. These in vivo-induced (ivi) proteins,
encoded by ivi genes, mapped to the backbone, O islands (OIs), and pO157. Lack of in vitro expression of
O157-specific ivi proteins was confirmed by proteomic analysis of a mid-exponential-phase culture of E. coli
O157 grown in LB broth. Because ivi proteins are expressed in response to specific cues during infection and
might help pathogens adapt to and counter hostile in vivo environments, those identified in this study are
potential targets for drug and vaccine development. Also, such proteins may be exploited as markers of O157
infection in stool specimens.
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157)
is a uniquely human pathogen that causes disease ranging from
acute, self-resolving watery diarrhea to hemorrhagic colitis and
the potentially fatal hemolytic-uremic syndrome (HUS). Cur-
rently, no therapies are available to lessen the potential mor-
bidity and mortality of this infection.
E. coli O157 is thought to have evolved from a strain of
enteropathogenic E. coli (EPEC) O55:H7 bearing the patho-
genicity island termed the locus for enterocyte effacement
(LEE), through the acquisition of bacteriophages encoding
Shiga toxins type 1 (stx1) and/or 2 (stx2), acquisition of a viru-
lence plasmid (pO157), transition of somatic antigen O55 to
O157, and loss of sorbitol fermentation and -glucuronidase
activity (21). HUS as a complication of E. coli O157 infection
has been associated with the presence of the stx2 gene or its
variant stx2c in the infecting E. coli O157 strain (21). In addi-
tion, the characteristic attaching and effacing (A/E) lesions
produced by this organism on the human colonic epithelium
are a result of proteins encoded on the LEE, including the
adhesion molecule intimin- (Eae), its receptor (Tir), the type
III protein secretion system, which secretes a variety of LEE-
encoded translocator proteins (EspA, EspB, and EspD) that
translocate effectors into host cells, and effector proteins (Tir,
EspG, EspF, Map, and EspH) that modulate the host cell
cytoskeleton (21). The type III secretion system translocates
Tir into the host cell, with subsequent trafficking to the host
cell membrane. Intimin binding of Tir leads to host cell actin
rearrangement and formation of A/E lesions. Other putative
virulence factors are encoded on pO157 and include an en-
terohemolysin (Ehx), an immunomodulator (Lif), and a serine
protease (EspP) (21). Hence several factors may be involved in
E. coli O157 pathogenesis, and research is ongoing to under-
stand the complexity of this infection.
The sequenced E. coli O157 EDL933 genome shows that
although this organism shares 4.1 Mb of DNA (termed back-
bone) with E. coli K-12, it has 1.34 Mb of DNA distributed
among 177 DNA segments termed O islands (OIs) that is
absent in K-12 (44). Of the genes found in these OIs, only 40%
have been assigned a function and several remain to be char-
acterized (44). Collective evidence indicates that intimin-
and the Shiga toxins act in concert with other, unidentified
virulence factors, encoded by both the OI and backbone se-
quences, to cause the spectrum of E. coli O157 disease (21, 54).
To date, the main impediment to identifying a broader com-
plement of virulence factors in this pathogen has been the lack
of an animal model that mimics the spectrum of human dis-
ease. Also, the potentially fatal sequelae that can follow E. coli
O157 infection preclude human volunteer studies. We circum-
vented these limitations and exploited the human immune
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response following E. coli O157 infection to identify a panel of
microbial factors that might contribute to the pathogenicity
of this organism. In particular, we used a modified immuno-
screening technique called in vivo-induced antigen technology
(IVIAT) (11), which enables identification of antigens ex-
pressed specifically during infection but not during growth in
standard laboratory media. The rationale was that such immu-
nogenic O157 antigens, expressed in response to unique signals
encountered within the gastrointestinal tract, might contribute
to pathogen adaptation and survival within the gut and hence
might play important roles in the virulence of this organism.
Here we report the identification of O157 proteins that are
expressed during human infection. We expect the proteins
identified to be potential targets for development of diagnos-
tics, drugs, and vaccines.
MATERIALS AND METHODS
Recombinant DNA methods. Isolation of plasmid DNA, restriction digestions,
and agarose gel electrophoresis were performed using standard procedures (48).
All enzymes for restriction digestions, DNA modifications, and ligations were
from New England Biolabs, Beverly, MA. DNA sequencing was performed at the
DNA Sequencing Core Facility, Department of Molecular Biology, Massachu-
setts General Hospital, using ABI Prism DiTerminator cycle sequencing with
AmpliTaq DNA polymerase FS and an ABI 377 DNA sequencer (Perkin-Elmer
Applied Biosystems Division, Foster City, CA). Oligonucleotides for PCR and
sequencing were obtained from the DNA Synthesis Core Facility, Department of
Molecular Biology, Massachusetts General Hospital. Plasmids were electropo-
rated into E. coli DH5 or BL21(DE3) using a Gene Pulser (Bio-Rad Labora-
tories, Richmond, CA) as instructed by the manufacturer. Electroporation con-
ditions were 2,500 V at 25-mF capacitance, producing time constants of 4.8 to
4.9 ms.
Bacterial strains, plasmids, and growth conditions. An isolate of E. coli O157,
from a patient who recovered from recent, clinically diagnosed HUS and con-
tributed a serum sample to the pool of convalescent-phase sera for probing the
expression library, was used to construct the DNA expression library (see below).
E. coli X21-Blue(pEB313) expressed an intracellular derivative of intimin-,
His6–intimin- (35), from which the putative signal sequence of 34 amino acids
had been removed (a gift of Alison O’Brien, Uniformed Services University of
the Health Sciences, Bethesda, MD.). E. coli DH5(pCVD468, pREP4) express-
ing a genetically engineered version of EspA, His6-EspA (22), was a gift from
James B. Kaper, University of Maryland School of Medicine, Baltimore, MD.
Bacterial strains were grown in vitro in Luria-Bertani (LB) medium and main-
tained at 70°C in LB broth containing 15% glycerol. Kanamycin (Kan) and
ampicillin (Amp) were used at concentrations of 50 g/ml and 100 g/ml,
respectively.
Patient and control sera. Convalescent-phase sera (approximately 500 l/
patient) were obtained from four patients who had recovered from HUS follow-
ing E. coli O157 infection. The ages of the patients ranged from 2 to 10 years, and
sera were collected on days 13 to 96 postillness. A serum sample from a healthy
pediatric patient was used as the control. All of the above serum samples were
collected at the Children’s Hospital and Regional Medical Center, Seattle, WA,
for routine laboratory investigations, and only excess sera were used for this
study. The Institutional Review Board of the Children’s Hospital and Regional
Medical Center approved the use of these sera, which were stored at 70°C until
use.
Assessment of reactivities of pooled, unadsorbed HUS convalescent-phase and
healthy control sera with immunogenic O157 proteins. Sera were assessed by
examining their reactivities via colony immunoblotting (described below) against
E. coli XL1-Blue(pEB313), expressing His6–intimin-, plated onto LB-Amp
plates (35) and against E. coli DH5(pCVD468, pREP4), expressing His6-EspA,
plated onto LB-Amp-Kan plates (22). Both EspA and intimin- are expressed
during human infection and targeted by the immune response (22, 35).
Adsorption of HUS convalescent-phase and control sera. To compensate for
variations in immune responses of individual patients and identify the widest
array of O157 antigens, equal volumes of HUS convalescent-phase serum sam-
ples from four patients were pooled and sequentially adsorbed against the E. coli
O157 isolate recovered from one of the four patients (the same E. coli O157
isolate used to generate the expression library).
The adsorption protocol has been described previously (12). Briefly, a protease
inhibitor cocktail formulated for bacterial cells and containing 4-(2-aminoethyl)
benzenesulfonyl fluoride (AEBSF; 23 mM), EDTA (100 mM), bestatin (2 mM),
pepstatin A (0.3 mM), and E-64 (0.3 mM) was prepared per the manufacturer’s
(Sigma, St. Louis, MO) instructions and then added to intact cells and cell lysates
at a dilution of 1:10. Pooled HUS convalescent-phase sera were sequentially
adsorbed against in vitro-grown (LB broth, 37°C) E. coli O157 whole cells, cell
lysates (prepared by three cycles of freezing and thawing, followed by sonica-
tion), and heat-denatured cell lysates (12). Adsorbed sera were stored at 70°C
until further use.
Individual HUS convalescent-phase serum samples from each of the four
patients and the control serum sample were adsorbed against whole cells, cell
lysates, and heat-denatured cell lysates of the in vitro-grown (LB-Kan broth,
37°C) expression host, E. coli BL21(DE3) containing the native pET-30abc
expression plasmids, in a similar manner.
The efficiency of adsorption of pooled HUS convalescent-phase sera was
assessed using an enzyme immunoassay described previously (12) and detailed
below. Adsorption efficiency was further evaluated by reacting sera with recom-
binant clones expressing His6–intimin- and His6-EspA via colony immunoblot-
ting as described below.
Efficiency of adsorption of pooled HUS convalescent-phase sera. Microtiter
wells were coated with 100 l of a 1:2 dilution of a lysate of in vitro-grown E. coli
O157 (the same isolate used to make the DNA expression library) in 50 mM
carbonate buffer (pH 9.6), prepared by three cycles of freezing and thawing
followed by sonication. Following overnight incubation at room temperature,
wells were washed with phosphate buffered saline (PBS) containing 0.05% of
Tween 20 (PBS-T) and blocked with a 1% solution of bovine serum albumin.
After a 1-h incubation at 37°C, wells were emptied, and 100 l dilutions (1:200
to 1:25,600) of sera, removed from the pool after each adsorption step, were
added to wells. The wells were incubated for 1 h at 37°C and washed, after which
100 l of a 1:1,000 dilution of horseradish peroxidase-conjugated goat anti-
human affinity-purified immunoglobulin G (IgG), reactive against all classes of
human immunoglobulins (ICN, Cappel, Aurora, OH), was added to the wells.
Wells were incubated for 1 h at 37°C and washed with PBS-T. Reactions were
developed with a 1-mg/ml solution of 2,2-azinobis(ethylbenzthiazolinesulfonic
acid) (ABTS; Sigma, St. Louis, MO) with 0.1% H2O2 (Sigma). The optical
density at 405 nm (OD405) was determined kinetically with a Vmax microplate
reader (Molecular Devices Corporation, Sunnyvale, Calif.). Plates were read for
5 min at 19-s intervals, and the maximum slope for an OD change of 0.2 U was
determined as milli-OD units/min (20).
Construction of an inducible E. coli O157:H7 genomic DNA expression li-
brary. Polymorphic amplified typing sequences, a powerful and user-friendly
typing methodology for bacterial pathogens that compares well with pulsed-field
gel electrophoresis (24, 25), profiled the cognate E. coli O157 isolates from the
four HUS patients as heterogeneous. We therefore selected one isolate at ran-
dom, purified genomic DNA, and generated the DNA expression library.
To generate the expression library, vector DNA was prepared by digesting with
the restriction enzyme BamHI (New England Biolabs, Beverly, MA). The vectors
used were the pET-30abc series of expression vectors (Novagen, Madison, WI),
which permit the cloning of inserts in each of the three reading frames under the
transcriptional control of the T7 phage promoter. The restriction enzyme-di-
gested plasmid DNA was gel purified using the QIAEX II gel extraction kit
(QIAGEN, Valencia, CA) and then treated with shrimp alkaline phosphatase.
Genomic DNA of an E. coli O157 isolate from one of the four HUS patients was
partially digested with the restriction enzyme Sau3AI. Following fractionation on
a 1% agarose gel, DNA fragments ranging from ca. 0.5 to 1.5 kbp (insert DNA)
were excised and purified using the QIAEX gel extraction kit (QIAGEN).
Various ratios of insert and vector DNA were ligated and used to transform
competent E. coli DH5 via electroporation according to standard protocols
(48). Transformants were plated onto LB plates supplemented with 50 g/ml of
Kan (LB-Kan). After an overnight incubation at 37°C, growth was scraped off the
plates and plasmid DNA was isolated using standard procedures (48) and used
to transform electrocompetent E. coli BL21(DE3) (Novagen), a general-purpose
expression host. To determine the percentage of transformants containing in-
serts, the library was plated onto LB-Kan plates, and 100 colonies were randomly
picked and analyzed by colony PCR using vector-specific primers. More than
90% of transformants contained inserts ranging from 0.2 kbp to 1.8 kbp.
Screening of the expression library and identification of clones expressing
immunogenic O157 proteins. The expression library was first screened with
pooled unadsorbed HUS convalescent-phase sera as follows. An optimal dilution
of the library in E. coli BL21(DE3) was plated onto LB-Kan plates to yield ca.
300 to 350 colonies per plate. After 5 h of incubation at 37°C, colonies were lifted
using a nitrocellulose filter and placed, colony side up, on fresh LB-Kan plates
containing 1 mM isopropyl--D-thiogalactoside. Plates were incubated overnight
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at 30°C to induce expression of genes contained within cloned inserts. Colonies
on plates were partially lysed by exposing them to chloroform vapors for 15 min
in a candle jar. The filters were removed from the plates, air dried, and blocked
using 5% nonfat milk in PBS (pH 7.4) for 1 h at room temperature. After a rinse
with PBS-T, the filters were probed with a 1:500 dilution of pooled unadsorbed
HUS convalescent-phase sera for 1 h at room temperature on a rocking platform.
Filters were washed three times with PBS-T and incubated with a 1:5,000 dilution
of peroxidase-labeled goat IgG directed against the human gamma globulin
fraction (ICN/Cappel). Following development with an ECL chemiluminescence
kit (Amersham Pharmacia Biotech), reactive clones were identified by their
positions on the reference plate (the original plate from which the colonies were
lifted, which was also incubated overnight at 30°C). Each reactive clone identified
in the primary screen was purified further, picked with a toothpick in a grid
pattern such that each test clone alternated with E. coli BL21(DE3)(pET-30a),
the negative control, and processed as described above.
Identification of O157 proteins expressed during human infection by using
IVIAT. To identify proteins expressed by E. coli O157 during human infection,
the clones identified above were subjected to IVIAT using pooled adsorbed HUS
convalescent-phase sera. Clones were picked with a toothpick onto LB-Kan plates in
a grid pattern and incubated for 5 h at 37°C. Processing of filters and screening
were identical to those described above, except that a 1:100 dilution of pooled
adsorbed HUS convalescent-phase sera was used as a probe. Following confir-
mation by four additional rounds of screening, plasmid inserts were sequenced
and encoded proteins were identified via BLAST against the genomic sequences
of E. coli O157:H7 strains EDL933 and Sakai. Proteins expressed from inserts
within positive clones were called in vivo-induced proteins (ivi proteins), and the
genes encoding them were referred to as ivi genes. Positive clones were further
probed with individual adsorbed HUS convalescent-phase serum samples from
each of the four patients and the control serum sample, as described above.
Cellular localization of ivi proteins was predicted using the PSORT/PSORT-B
program (http://psort.nibb.ac.jp/). Hypothetical ivi proteins were assigned puta-
tive functions using the Clusters of Orthologous Groups (COGs) database,
available at http://www.ncbi.nlm.nih.gov/COG/. The online browser tool Pro-
teome Navigator was used to compare proteins not assigned specific functions by
the COGs database against Prolinks, a database of protein functional linkages
derived from coevolution (2), available at http://dip.doe-mbi.ucla.edu/pronav.
Proteomic analysis of E. coli O157 grown in LB broth using ESILC-MS/MS.
To determine whether ivi proteins were expressed when E. coli O157 was cul-
tured under standard laboratory conditions, E. coli O157 grown in LB broth was
subjected to microcapillary high-performance liquid chromatography combined
with electrospray ionization tandem mass spectrometry (ESILC-MS/MS) at the
Harvard Partners Center for Genetics and Genomics, Cambridge, MA. The E.
coli O157 whole cells for one-dimensional LC-MS/MS analysis were prepared
as follows. Mid-log-phase E. coli O157 (OD600, 0.7), cultured at 37°C in LB
broth, was pelleted via centrifugation at 4°C and washed twice in deionized water.
Cells were aliquoted into 1.5-ml tarred centrifuge tubes, frozen at 80°C, and
lyophilized to dryness under a high vacuum. The tubes were then weighed again
and the total dried cell pellet weight determined. Dried E. coli O157 pellets (2
mg) were dissolved in 200 l of 6 M urea, 1% sodium dodecyl sulfate, 100 mM
ammonium bicarbonate, and 10 mM dithiothreitol (pH 8.5). Samples were vor-
texed, and following incubation at 37°C for 1 h, 12 l of 500 mM iodoacetamide,
100 mM ammonium bicarbonate (pH 8.5) was added to each 200-l sample. The
reaction was allowed to proceed at room temperature for 1 h in the dark. Al-
kylation was quenched by the addition of 2 l of 2 M dithiothreitol in 100 mM
ammonium bicarbonate, pH 8.5. Samples were then diluted eightfold with 5 mM
CaCl2, mixed with 20 g of Promega sequencing-grade trypsin, and incubated at
37°C for 16 h. Following quenching with 2 l of formic acid, samples were diluted
with 2 ml of 0.1% formic acid and cleaned up using a Waters Oasis MCX car-
tridge. Peptides were eluted with 6% ammonium hydroxide in 50% acetonitrile,
frozen, and lyophilized. Samples were redissolved in 5% acetonitrile–0.1% formic
acid/water and loaded onto a 96-well plate for mass spectrometry (MS) analysis.
For MS, samples were run on an LCQ DECA XP plus Proteome X worksta-
tion from Thermo Finnigan. For each run, 85 l of reconstituted sample was
injected with a Surveyor Autosampler, while the separation was done on a
250-m (inner diameter) by 30-cm column packed with C18 medium running at
a 2-l-per-minute flow rate provided from a Surveyor MS pump with a flow
splitter, with a gradient of 5 to 72% water, 0.1% formic acid, and 5% acetonitrile
over the course of 240 min (4 h). Two such runs were performed. Between each
set of samples, two standards of a 5 Angio mix of peptides (Michrom BioRe-
sources) were run to ascertain column performance and observe any potential
carryover. The LCQ was run in a top five configuration, with one MS scan and
five MS/MS scans. Dynamic exclusion was set to 1, with a limit of 30 seconds.
Peptide identifications were made using SEQUEST (Thermo Finnigan) through
the Bioworks Browser 3.1. Sequential database searches were made using the E.
coli O157:H7 strain EDL933 FASTA database from the European Bioinformat-
ics Institute (http://www.ebi.ac.uk/newt/display) of the European Molecular Bi-
ology Laboratory using differential carbamidomethyl-modified cysteines and ox-
idized methionines. A yeast protein database was spiked in to provide noise and
determine the validity of the peptide hits. In this fashion, known and theoretical
protein hits can be found without compromising the statistical relevance of all
the data (43). Peptide score cutoff values were chosen at cross-correlation values
(Xcorr) of 1.8 for singly charged ions, 2.5 for doubly charged ions, and 3.0 for
triply charged ions, along with deltaCN values of 0.1 and cross-correlation nor-
malized values of 1. The Xcorr chosen for each peptide ensured a high confi-
dence match for the different charge states, while the delta rank scoring prelim-
inary cutoff ensured the uniqueness of the peptide hit; the RSP value of 1
ensured that the peptide matched the top hit in the preliminary scoring.
RESULTS AND DISCUSSION
Pooled unadsorbed HUS convalescent-phase sera reacted
specifically with previously identified immunogenic O157 pro-
teins. Pooled unadsorbed HUS convalescent-phase sera re-
acted strongly and specifically with E. coli XL1-Blue(pEB313)
(35) and E. coli DH5(pCVD468, pREP4) (22), expressing
His6–intimin- and His6-EspA, respectively, in contrast to
E. coli BL21(DE3) expressing recombinant Vibrio cholerae
PilA, an irrelevant control protein (Fig. 1A). This suggested
that the pool of sera possessed sufficient reactivity for prob-
ing the expression library. On the other hand, the unabsorbed
healthy-control serum did not react with either of these pro-
teins (data not shown).
Adsorption of pooled HUS convalescent-phase sera as per
the IVIAT protocol resulted in selective depletion of antibodies
against O157 antigens expressed in vitro. Adsorption effi-
ciency was determined by examining the reactivities of serum
aliquots from pooled HUS convalescent-phase sera after each
adsorption step with lysates of in vitro-grown E. coli O157.
There was a sharp decline in the reactivities of sera against the
lysates of in vitro-grown E. coli O157 following the first ad-
sorption step compared to those of the unadsorbed sera, indi-
cating efficient depletion of antibodies against in vitro-ex-
pressed O157 proteins (Fig. 2).
Although the adsorbed sera continued to react with the
clone expressing His6–intimin-, it did not react with the clone
expressing His6-EspA (Fig. 1B). Since both are reportedly ex-
pressed during human infection (22, 29), as well as during in
vitro growth (36), we anticipated reactivity with both might be
eliminated by adsorption of the sera. We attribute the residual
serum reactivity with intimin- to relatively weak in vitro ex-
pression of this protein, which may be insufficient to adsorb
away all of the anti-intimin- antibodies generated in response
FIG. 1. Reactivities of pooled unadsorbed (A) and adsorbed (B)
HUS sera against two known E. coli O157 virulence proteins, inti-
min and EspA, and an unrelated negative-control protein, PilA, from
V. cholerae.
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to significantly higher expression of this adhesin within the
gastrointestinal tract.
Screening of an E. coli O157 genomic expression library.
Primary screening of ca. 50,000 clones of an E. coli O157 ge-
nomic expression library, using pooled unadsorbed HUS con-
valescent-phase sera, yielded 918 reactive clones. IVIAT of
these clones using pooled adsorbed HUS convalescent-phase
sera identified 223 persistently reactive clones containing unique
inserts as determined from nonredundant databases.
ivi proteins included previously identified E. coli O157 vir-
ulence-related proteins. IVIAT identified four proteins previ-
ously reported to have a putative role in E. coli O157 virulence
(1) (Table 1). (i) Intimin- is a LEE-encoded outer membrane
adhesin that acts in concert with other LEE-encoded proteins
to generate the A/E lesion (21) and to effect binding to host
nucleolin (50) to tether the bacterium to the enterocyte. (ii)
QseA, a backbone-encoded LysR-type quorum-sensing E. coli
transcriptional regulator, is part of the regulatory cascade that
controls expression of O157 virulence factors via quorum sens-
ing (52). QseA is also present in other gastrointestinal patho-
gens such as EPEC (QseA) and V. cholerae (AphB). Following
activation by the furanone AI-2, QseA activates transcription
of Ler, the positive activator of the LEE operon, and there-
by influences expression of putative virulence factors from
the LEE. A qseA mutant is impaired in the secretion of LEE-
encoded proteins via the type III secretion system, also encod-
ed on the LEE (53). (iii) TagA, a pO157-encoded inner mem-
brane lipoprotein (41), is a protein of unknown function, but a
putative role in E. coli O157 virulence has been suggested
because of its presence in a diverse collection of E. coli O157
strains (41) and the fact that a homolog in V. cholerae is reg-
ulated by ToxR, a transcriptional regulator that governs expres-
sion of several V. cholerae virulence factors (13). (iv) MsbB2, a
pO157-encoded inner membrane acyltransferase, facilitates
the synthesis of hexaacyl lipid A, the form with maximal bio-
logical activity (23). MsbB2 reportedly functions to suppress
minor modifications of lipid A. Acting in conjunction with
MsbB1, another homologous acyltransferase expressed from
the chromosome, MsbB2 facilitates the synthesis of lipid A of
maximal biological activity, which interacts optimally with the
host immune system to evoke an immune response to LPS
(23). Strongly supporting a role for MsbB2 in E. coli O157
virulence is the fact that LPS reportedly acts synergistically
with the Shiga toxins, especially Stx2, in the pathogenesis of
HUS (19). Further support for a likely role in E. coli O157
virulence is suggested by observations that MsbB2 contributes
to the virulence of related pathogens such as Shigella flexneri
and septicemic E. coli O18:K1:H7 strain H16 and that it influ-
ences the expression of virulence-related surface structures in
diverse pathogens (23).
ivi proteins expressed from the E. coli O157 backbone. A
total of 181 ivi proteins of diverse functional classes were
expressed from the backbone (Table 2). Those involved in bio-
synthesis and metabolism (51.38%) may have functions essen-
tial for bacterial growth in vivo, a feature imperative for bac-
terial pathogenicity. Also, consistent with the anaerobic gut
environment, IVIAT identified glycolytic enzymes, hydroge-
nases involved in fermentation of carbon compounds, an
alcohol dehydrogenase, and reductases (including two cryptic
nitrate reductases) involved in energy generation from carbo-
hydrates via anaerobic respiration and fermentation (42).
These results were expected and consistent with those of other
studies of diverse organisms using techniques such as transcrip-
tional profiling (59), in vivo expression technology (15, 33), re-
combinase in vivo expression technology (4), signature-tagged
mutagenesis (14, 37, 38), selective capture of transcribed se-
quences (SCOTS) (7), and IVIAT of other organisms (5).
Transport ivi proteins (18.78%) included diverse ABC-type
transporters and phosphotransferase systems (PTS), per-
meases, transport proteins involved in the transport of diverse
molecules, iron uptake proteins such as FhuA (a transporter of
ferrichrome [Fe3] and a receptor for phages and colicins),
CirA, an iron-regulated receptor for uptake and transport of
colicin I, uncharacterized transport proteins, and, in particular,
an anaerobically induced permease, TdcC, expressed from the
tdc operon, which encodes the transport and degradation of
L-threonine and L-serine. Inactivation of the activator, TdcA,
FIG. 2. Enzyme immunoassay reactivities of sera with lysates of in
vitro-grown E. coli O157 after each step in sequential adsorption.
OD405 values were corrected for background and for dilution during
adsorption.









No. of reactive serac
HUS sera Control serum
H-310 OI 148 eae/intimin/attaching and effacing Outer membrane AE005595 4 0
H-13, -75 pO157 msbB2/MsbB/lipid A acyltransferase Inner membrane AF074613 4 0
H-124 pO157 L7031/probable toxR-regulated lipoprotein TagA Inner membrane AF074613 4 0
H-314 Backbone qseA/transcriptional regulator, LysR type;
quorum-sensing E. coli regulator A
Cytoplasm AE005552 4 0
a Putative functions of hypothetical proteins determined from the COGs database when available.
b Predicted by the PSORT/PSORT-B program.
c Sera from four patients with HUS and one healthy person were tested individually.
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H-5, -20 topA/DNA topoisomerase type I, omega protein/DNA replication, repair,
restriction/modification
Cytoplasm AE005379 4 0
H-9 dsbA/protein disulfide isomerase I, essential for cytochrome c synthesis and
formate-dependent reduction/protein translation and modification
Periplasm AE005616 4 0
H-22, -23 crcB/putative protein involved in chromosome condensation Inner membrane AE005242 4 0
H-37 purK/phosphoribosylaminoimidazole carboxylase (AIR carboxylase), CO2-
fixing subunit/purine ribonucleotide biosynthesis
Cytoplasm AE005233 4 0
H-40 purD/phosphoribosylglycinamide synthetase (GAR synthetase)/purine
ribonucleotide biosynthesis
Cytoplasm AE005632 4 0
H-42 apbA/thiamine biosynthesis, alternate pyrimidine biosynthesis Inner membrane AE005221 4 0
H-110 recR/DNA replication, repair, restriction/modification Cytoplasm AE005487 4 0
H-121 cysD/ATP:sulfate adenylytransferase, subunit 2 Cytoplasm AE005502 4 0
H-145, -183 glgP/glycogen phosphorylase/polysaccharide modification Cytoplasm AE005566 4 0
H-211 mutH/methyl-directed mismatch repair/DNA replication, repair, restriction/
modification
Cytoplasm AE005512 4 1
H-230 Z2851/putative Rad3-related DNA helicase Cytoplasm AE005403 1 0
H-245, -260 dfp/flavoprotein affecting synthesis of DNA and pantothenate metabolism/
DNA replication, repair, restriction/modification
Inner membrane AE005591 4 0
H-313 mutS/methyl-directed mismatch repair/DNA replication, repair, restriction/
modification
Cytoplasm AE005501 4 0
Small-molecule
synthesis
H-11 ggt/gamma-glutamyltranspeptidase/biosynthesis of cofactors, carriers:
thioredoxin, glutaredoxin, glutathione
Periplasm AE005568 4 1
H-60 Z3637/putative thiamine pyrophosphate-requiring enzyme—isoleucine,
leucine, valine biosynthesis
Cytoplasm AE005468 4 0
H-71 dapD/2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyl transferase/amino
acid biosynthesis: lysine
Cytoplasm AE005192 2 1
H-116, -137 glyA/serine hydroxymethyltransferase/amino acid biosynthesis: glycine Inner membrane AE005485 4 0
H-117 accC/acetyl-CoA carboxylase, biotin carboxylase subunit/fatty acid and
phosphatidic acid biosynthesis
Cytoplasm AE005553 4 0
H-131, -133 hemK/putative protoporphyrinogen oxidase/biosynthesis of cofactors: heme,
porphyrin
Cytoplasm AE005338 4 0
H-132 alaS/alanyl-tRNA synthetase/tRNA modification Inner membrane AE005498 4 0
H-164 folE/GTP cyclohydrase/biosynthesis of cofactors, carriers: folic acid Cytoplasm AE005447 4 0
H-174 nadE/NAD synthetase/biosynthesis of cofactors, carriers: pyridine Cytoplasm AE005397 4 0
H-177 hisS/histidine-tRNA synthetase/tRNA modification Inner membrane AE005480 4 1
H-194 Z2789/putative thiosulfate sulfur-transferase Periplasm AE005398 4 0
H-227 cstC/acetylornithine delta-aminotransferase/amino acid biosynthesis: arginine Inner membrane AE005397 4 0
H-267 lysS/lysine-tRNA synthetase/tRNA modification Cytoplasm AE005519 4 0
H-279, -280, -282,
-283, -308, -312
proB/gamma-glutamate kinase/amino acid biosynthesis: proline Inner membrane AE005202 4 0
Macromolecule
degradation
H-79 hycI/protease/processing of C-terminal end of the large subunit of
hydrogenase 3
Cytoplasm AE005500 2 0
H-99 Z5946/putative restriction endonuclease S subunits Cytoplasm AE005666 2 0
H-100, -253 Z3649/putative cellulase M and related protein Cytoplasm AE005469 4 0
H-140, -154, -215,
-218, -219, -222
dcp/dipeptidyl carboxypeptidase II/degradation of proteins, peptides,
glycopeptides
Cytoplasm AE005351 4 0
H-173 Z1305/putative ATP-dependent protease Inner membrane AE005285 2 0
H-185 malS/alpha-amylase/degradation of polysaccharides Periplasm AE005584 4 0
H-188 uvrB/excision nuclease subunit B/degradation of DNA Cytoplasm AE005259 4 0
H-236 Z2427/putative metal-dependent amidase/aminoacylase/carboxypeptidase Cytoplasm AE005372 4 0
H-242 exo/5–3 exonuclease/degradation of DNA Inner membrane AE005508 4 0
H-304, -307, -309 endA/endonuclease I/degradation of DNA Periplasm AE005525 4 0
Small-molecule
degradation
H-7 fadA/thiolase I/degradation of fatty acids Cytoplasm AE005615 4 0
H-8 rnt/RNase T/degrades tRNA Cytoplasm AE005388 4 0
H-46, -67 xylA/D-xylose isomerase/degradation of carbon compounds Cytoplasm AE005583 4 0
H-58 Z0666/putative dihydroorotase and related cyclic amidohydrolases Cytoplasm AE005232 4 0
H-74 hflB/integral membrane peptidase/degrades sigma 32 Inner membrane AE005546 4 0
Continued on following page
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H-91, -93 malY/enzyme that blocks biosynthesis or degrades endogenous Mal inducer,
probably aminotransferase/degradation of carbon compounds
Cytoplasm AE005386 4 0
H-104 galK/galactokinase/degradation of carbon compounds Inner membrane AE005253 4 0
H-166 celF/phosphor-beta-glucosidase/degradation of carbon compounds Cytoplasm AE005396 4 0
H-175 treF/trehalase/degradation of carbon compounds Inner membrane AE005577 4 0
H-178, -241 yciA/putative acyl-CoA hydrolase Cytoplasm AE005342 2 0
H-301 malZ/maltodextrin glucosidase/degradation of carbon compounds Inner membrane AE005219 4 0
Energy/metabolism
H-3 yhaF/putative 2,4,-dihydroxyhept-2-ene-1,7-dioic acid aldolase Cytoplasm AE005541 4 0
H-16 Z2579/putative dimethyl sulfoxide reductases Inner membrane AE005382 4 0
H-19 Z2779/putative arginine/ornithine N-succinyl transferase beta subunit Cytoplasm AE005397 4 0
H-29 fba/fructose-bisphosphate aldolase, class II/glycolysis Cytoplasm AE005522 4 0
H-35 Z2723/putative oxidoreductase Cytoplasm AE005392 4 0
H-39 hycG/hydrogenase/carbon fermentation Cytoplasm AE005500 4 0
H-49, -50, -52,
-53, -134
adhP/alcohol dehydrogenase/anaerobic respiration Cytoplasm AE005357 4 0
H-54 ycaH/putative tetraacyldisaccharide-1-P4-kinase Cytoplasm AE005281 4 1
H-72 narW/cryptic nitrate reductase 2, delta subunit/anaerobic respiration Cytoplasm AE005359 4 0
H-85 dmsC/dimethyl sulfoxide reductase, subunit C/anaerobic respiration Inner membrane AE005279 4 0
H-88 ccmH/possible subunit of heme lyase/electron transport Inner membrane AE005452 4 1
H-103, -165 ygjL/putative NADPH dehydrogenase Inner membrane AE005538 4 0
H-105 nrfE/formate-dependent nitrite reductases/anaerobic respiration Inner membrane AE005640 4 0
H-108 phoA/alkaline phosphatase/central intermediary metabolism Periplasm AE005217 4 1
H-111 yhdJ/putative methyltransferase Cytoplasm AE005554 4 0
H-114, -142 visC/putative 2-polyprenyl-6-methoxyphenol hydroxylase and related
FAD-dependent oxidoreductases
Inner membrane AE005521 4 0
H-118 citF/citrate lyase alpha chain/central intermediary metabolism Inner membrane AE005241 4 0
H-122 yleB/putative 2-polyprenyl-6-methoxyphenol hydroxylase and related
FAD-dependent oxidoreductases
Inner membrane AE005245 4 0
H-138 citE/citrate lyase beta chain/central intermediary metabolism Inner membrane AE005241 4 0
H-147 ygfZ/putative aminomethyltransferase related to GcvT Cytoplasm AE005520 4 0
H-149 nrdB/ribonucleoside diphosphate reductase, beta subunit, B2/central
intermediary metabolism
Cytoplasm AE005456 4 0
H-153 agaV/N-acetylgalactosamine-specific IIB component 2 (EIIB-AGA)/central
intermediary metabolism
Inner membrane AE005542 4 0
H-160, -264 Z4220/putative dehydrogenase Inner membrane AE005518 4 0
H-167 nuoL/NADH dehydrogenase I, chain L/anaerobic respiration Inner membrane AE005460 4 1
H-171, -306 hybD/probable processing element for hydrogenase-2/anaerobic respiration Inner membrane AE005529 4 0
H-186 nuoM/NADH dehydrogenase I, chain M/anaerobic respiration Inner membrane AE005459 4 1
H-205 Z3775/putative dehydrogenase Outer membrane AE005480 4 0
H-216 Z4018/putative flavodoxin Cytoplasm AE005499 4 0
H-217, -221, -223 Z5951/putative GTPase (G3E family) Cytoplasm AE005666 4 0
H-224 yhjL/putative oxidoreductase Cytoplasm AE005579 4 0
H-233, -288 narY/cryptic nitrate reductase 2, beta subunit/anaerobic respiration Cytoplasm AE005359 4 0
H-237 solA/putative sarcosine oxidase-like protein Periplasm AE005316 2 0
H-239 yidS/putative dehydrogenase (flavoprotein) Cytoplasm AE005600 4 0
H-244 ugd/UDP-glucose-6-dehydrogenase/central intermediary metabolism Inner membrane AE005428 4 0
H-254 yliI/putative dehydrogenase Periplasm AE005265 4 0
H-258 Z3401/putative oxidoreductase Inner membrane AE005446 4 0
H-270, -276 epd/D-erythrose-4-phosphate dehydrogenase/central intermediary metabolism Cytoplasm AE005523 4 0
H-277 ybjT/putative dTDP-glucose enzyme Inner membrane AE005268 4 0
H-287 yraL/putative methyltransferase Cytoplasm AE005543 4 0
H-292 Z3734/putative metalloprotease Inner membrane AE005477 4 0
H-295 yeaA/putative peptide methionine sulfoxide reductases Cytoplasm AE005401 4 0
H-300 wecB/UDP-N-acetyl glucosamine-2-epimerase/central intermediary metabolism Cytoplasm AE005610 4 0
H-305 tktA/transketolase 1 isoenzyme/central intermediary metabolism Cytoplasm AE005524 4 0
H-315 pflD/formate acetyltransferase 2/anaerobic respiration Cytoplasm AE005626 4 0
Regulatory
H-1 basS/BasS/sensor protein for BasR, involved in macromolecule synthesis Inner membrane AE005644 4 0
H-14 phoQ/PhoQ/sensor protein; global regulation Inner membrane AE005328 4 0
H-24 mopB/GroES chaperone/folding and ushering proteins Cytoplasm AE005648 2 0
H-27 pqiA/paraquat-inducible protein A/not characterized Inner membrane AE005285 4 1
H-45, -87, -290,
-293
xylR/XylR/regulates the xyl operon, involved in xylose utilization Cytoplasm AE005583 4 0
H-81, -83 ydeW/putative transcriptional regulator Inner membrane AE005353 4 0
H-82 glnG/GlnG/response regulator for gln operon, involved in glutamine
biosynthesis; interacts with sensor GlnL
Cytoplasm AE005617 4 0
Continued on following page
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H-86 rcsF/RcsF/regulates the rcs regulon, involved in colanic acid synthesis;
interacts with rcsB
Outer membrane AE005195 4 0
H-94 yieP/putative transcriptional regulator Cytoplasm AE005607 4 1
H-120, -148 glnL/GlnL/histidine protein kinase sensor for the GlnG regulator; glutamine
biosynthesis
Inner membrane AE0055617 4 1
H-127 yifB/putative 2-component regulator Periplasm AE005608 4 1
H-141 uidR/UidR/regulates the uid operon, involved in beta-glucuronidase synthesis Cytoplasm AE005385 4 0
H-159 prpR/PrpR/regulates the prp operon, involved in propionate catabolism Cytoplasm AE005212 4 1
H-192 yfeR/putative transcriptional regulator, LysR type Cytoplasm AE005471 4 0
H-193 uvrY/putative 2-component regulator Cytoplasm AE005414 4 0
H-195 ybcZ/putative 2-component sensor Inner membrane AE005236 4 0
H-201 yeiL/putative transcriptional regulator Inner membrane AE005448 4 0
H-256 yifA/putative transcriptional regulator Cytoplasm AE005607 4 0
H-262 fucR/FucR/positive regulator of the fuc operon Cytoplasm AE005508 4 0
H-274 fliS/FliS/regulates flagellar biosynthesis Cytoplasm AE005415 4 0
H-278 hydH/HydH/sensor kinase for HydG, hydrogenase 3 activity Inner membrane AE005632 4 0
H-297 narX/NarX/nitrate/nitrate sensor, histidine protein kinase, acts on NarL
regulator
Inner membrane AE005339 2 0
H-303 yhjC/putative transcriptional regulator, LysR type Inner membrane AE005577 4 0
H-311 Z2724/putative Arac-type regulator Cytoplasm AE005392 4 0
Transport
H-4, -289 ascF/AscF; PTS system enzyme II/transport of small molecules: arbutin,
salicin, cellobiose
Inner membrane AE005500 4 0
H-10 ybhS/putative ABC-type multidrug transport system, permease component Inner membrane AE005260 4 1
H-12 wzxC/putative export protein; protein, peptide secretion Inner membrane AE005430 4 0
H-15 flhB/export of flagellar proteins Inner membrane AE005410 4 0
H-28 yohM/putative ABC-type uncharacterized transport system, permease component Inner membrane AE005437 4 0
H-31 tdcC/TdcC; anaerobically induced permease/transport of amino acids:
L-threonine, L-serine
Inner membrane AE005540 4 0
H-34 malF/MalF; permease/transport of small molecules: maltose Inner membrane AE005636 4 0
H-44, -200, -213,
-250, -251, -286
yegT/putative nucleoside permease Inner membrane AE005436 4 0
H-47, -66, -266 ycbQ/putative chaperone Outer membrane AE005284 4 0
H-59 yedE/putative transport system permease protein Inner membrane AE005415 4 0
H-73 Z4150/putative transport protein Inner membrane AE005512 4 0
H-76 yhfC/putative transport protein Inner membrane AE005559 4 0
H-92 yaeM/putative ATP-binding component of transport system Inner membrane AE005193 4 0
H-101 Z2654/putative chaperone distantly related to HSP70-fold metalloprotease Cytoplasm AE005387 4 0
H-109, -168, -169,
-172, -182, -184
livG/LivG; ATP-binding component of high-affinity branched-chain amino
acid transport system/transport of amino acids, amines
Cytoplasm AE005569 4 0
H-115 ugpC/UgpC; ATP-binding component of glycerol-3-phosphate transport sys-
tem/transport of small molecules: carbohydrates, organic acids, alcohols
Cytoplasm AE005568 4 0
H-125, -275 ycdG/putative xanthine/uracil permease Inner membrane AE005300 4 0
H-126 kefC/KefC/transport of cations: K efflux antiporter, glutathione regulated Inner membrane AE005181 4 0
H-143 Z3262/putative ADP-ribosylglycohydrolase Inner membrane AE005436 4 0
H-163 yhfM/putative amino acid/amine transport protein Inner membrane AE005560 2 0
H-176 Z5178/putative PTS component; transport of carbohydrates, organic acids,
alcohols
Inner membrane AE005600 4 0
H-187 wzb/putative tyrosine phosphatase Inner membrane AE005432 4 0
H-197 kgtP/KgtP; alpha-ketoglutarate permease/transport of small molecules:
carbohydrates, organic acids, alcohols
Inner membrane AE005489 4 0
H-202, -261 fhuA/FhuA/transport of ferrichrome (Fe3) and antibiotics, acts as a
receptor for phages and colicins
Outer membrane AE005191 4 0
H-206 nagE/NagE; PTS system N-acetylglucosamine-specific enzyme IIABC/
transport of amino acids, amines
Inner membrane AE005246 4 0
H-225 sgaB/putative PTS, galactitol-specific IIB component Cytoplasm AE005652 4 0
H-226 Z2786/putative ABC-type uncharacterized transport system, periplasmic
component
Periplasm AE005398 4 0
H-228 yaaU/putative transport protein Inner membrane AE005181 4 0
H-240 cycA/CycA; permease/transport of amino acids and amines: D-alanine,
D-serine, glycine
Inner membrane AE005653 4 0
H-252 oppB/OppB; oligopeptide transport permease protein/transport of large
molecules: proteins, peptides
Inner membrane AE005342 4 0
H-271 Z5839/putative ATP-binding component of ABC-type transport system Inner membrane AE005655 4 0
H-273 Z3589/putative transporting ATPase Cytoplasm AE005464 4 0
H-296 araG/AraG; ATP-binding component of high-affinity L-arabinose transport
system/transport of small molecules: L-arabinose
Inner membrane AE005411 2 1
H-316 Z2605/putative arginine/ornithine antiporter Inner membrane AE005384 4 0
Continued on following page
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results in hyperadherence of E. coli O157 to cultured epithelial
cells due to derepression of OmpA expression (54).
Regulatory proteins (13.81%) comprised, among others,
QseA, a LysR-type transcriptional activator (described above)
(52), and several two-component regulatory systems that gov-
ern the virulence of diverse pathogens (17). Some of these are
functionally interlinked, as evidenced by earlier reports (8, 10,
16, 58) and the Prolinks database, suggesting that IVIAT iden-
tified proteins that sense and integrate diverse environmental
signals (such as anaerobiosis, cation limitation, acid, and ex-
cess, toxic levels of extracytoplasmic Fe3) and help E. coli
O157 mount a coordinated cellular adaptive response to counter
the hostile host environment. The two-component regulatory
systems IVIAT identified were (i) the sensor molecule, NarX,
of the NarL-NarX system, which in the absence of oxygen
responds to nitrate or nitrite and acts via NarL, the response
regulator that activates expression of enzymes involved in ni-
trate respiration and represses enzymes involved in respiration
of other electron acceptors (27, 46); (ii) the sensor kinase
component, PhoQ, of the PhoP-PhoQ system, which responds
to extracytoplasmic levels of Mg2 and Ca2 (involved in the
adaptation to Mg2 limitation) (8) and to Zn2 excess (10);
(iii) the sensor component, BasS, of the BasR-BasS system,
which governs the response to excess extracytoplasmic Fe3
(58) and mild acid pH (51); (iv) the sensor protein, GlnL, of
the GlnG-GlnL system, which responds to low ammonia con-
centrations and stimulates ammonia assimilation (40); and (v)
HydH, the sensor for HydG, which primarily responds to high
periplasmic Zn2 and Pb2 concentrations and nonspecifically



















H-30 trg/Trg; methyl-accepting chemotaxis protein III, ribose sensor receptor/
regulator; chemotaxis and motility
Inner membrane AE005363 4 0
H-36 osmY/OsmY; hyperosmotically inducible protein/osmotic adaptation Periplasm AE005668 4 0
H-41, -130, -152, -265 yjbB/putative alpha-helix protein Inner membrane AE005634 4 0
H-55 ftsI/peptidoglycan synthetase/septum formation Inner membrane AE005185 4 0
H-62, -63, -64, -65 mepA/murein D,D-endopeptidase/cell envelope synthesis Periplasm AE005464 4 0
H-77 sfmH/SfmH/fimbrial assembly Inner membrane AE005234 4 0
H-95 yaeH/putative structural protein Cytoplasm AE005192 4 0
H-96 cirA/CirA/receptor for iron-regulated colicin I Outer mem-
brane
AE005447 4 0
H-150 yhjD/putative membrane protein Inner membrane AE005577 4 1
H-203 Z3481/putative membrane protein Inner membrane AE005454 4 0





H-246 slt/soluble lytic murein transglycosylase/murein sacculus synthesis Inner membrane AE005670 4 0
H-268 tsr/methyl-accepting chemotaxis protein I, serine sensor receptor/regulator,
chemotaxis and motility
Inner membrane AE005667 4 0
H-281 mdaA/MdaA/modulator of drug activity A Cytoplasm AE005266 4 0
H-284 yibP/putative membrane protein Inner membrane AE005588 4 0




H-209 Z1782/unknown, encoded within CP-933N Inner membrane AE005323 4 0
H-238 hflX/GTP-binding subunit of protease specific for lambda cII repressor/
degradation of proteins, peptides, glycopeptides
Cytoplasm AE005650 2 0
Unknown
H-43, -208, -291 yfiH/uncharacterized conserved protein Cytoplasm AE005490 4 0
H-57 ydbD/unknown Periplasm AE005365 4 0
H-68, -69 ychA/uncharacterized conserved protein Cytoplasm AE005338 4 0
H-80 yfbB/putative enzyme Inner membrane AE005458 2 0
H-97 ybfE/unknown Cytoplasm AE005246 4 1
H-157 yacC/unknown Cytoplasm AE005188 4 0
H-170 Z4888/unknown Inner membrane AE005573 4 0
H-179 yciI/unknown Inner membrane AE005342 4 0
H-190 yjjX/unknown Cytoplasm AE005670 2 0
H-198 yaaH/unknown Inner membrane AE005177 4 0
H-212 ybiM/unknown Inner membrane AE005261 4 1
H-243 Z2619/unknown Outer mem-
brane
AE005385 4 0
a Based on homology to the sequenced E. coli O157 strain EDL933 genome. Putative functions of hypothetical proteins were determined from the COGs database
when available.
b Predicted by the PSORT/PSORT-B program.
c Sera from four patients with HUS and one healthy person were tested individually.
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in hydrogen production during fermentation (28). IVIAT also
identified an outer membrane lipoprotein, RcsF, that trans-
duces a signal in response to glucose and zinc to the RcsC/
YojN/RcsB/RcsA phosphorelay system, which in turn controls
the rcs regulon (target genes), encoding enzymes for the col-
anic acid exopolysaccharide capsule (10), an acid-adaptive re-
sponse that protects E. coli O157 from environmental stresses
such as acid and heat (34). Other ivi proteins that were part of
this functional group and likely to impact in vivo survival of
E. coli O157 were (i) PrpR, a regulator of the prp operon in-
volved in the catabolism of propionate, a short-chain fatty acid
(SCFA) that can be detrimental to E. coli O157 at high con-
centrations (exposure to SCFA is a stress condition, and ca-
tabolism may serve to decrease the concentration of this SCFA
[26, 45]); (ii) FucR, a positive regulator of the fuc operon en-
coding enzymes for metabolism of L-fucose, a component of
both mucus and glycans on enterocytes (42) (following exper-
imental inoculation of mice, E. coli O157 reportedly is found
attached to both mucus and enterocytes [in contrast to non-
pathogenic E. coli, which is found in mucus alone] [39] and
may utilize L-fucose as one nutrient source to multiply and
outcompete other flora to establish infection); (iii) FliS and
FliT, which along with FliD negatively regulate the export of
the anti-sigma factor, FlgM, to prevent expression of the flagel-
lar regulon (which may promote in vivo survival, since over-
production of flagella is deleterious to bacterial growth) (61);
and (iv) paraquat-inducible protein A (PqiA), an inner mem-
brane protein of uncharacterized function.
ivi proteins functioning in environmental adaptation (8.84%)
included methyl-accepting chemotaxis proteins (MCPs), a pro-
tein that was part of the adaptive response to hyperosmolarity,
a colicin expressed in response to iron-limiting conditions, a
modulator of drug activity, and two proteins of the PhoB regu-
lon expressed as part of the adaptive response to phosphate
limitation. Specifically, IVIAT identified two MCPs, namely,
Trg, a receptor for the periplasmic ribose and galactose bind-
ing proteins, and Tsr, the serine sensor receptor, both of which
are regulators of chemotaxis and motility (40). Interestingly,
MCPs were also highly expressed during human infection with
V. cholerae as identified by IVIAT (12). IVIAT also identified
OsmY, a periplasmic protein of unknown function that is in-
duced in response to hyperosmolarity (60). This protein is
expressed as part of the Rcs regulon, which includes genes
encoding the synthesis of the exopolysaccharide colanic acid
capsule (see above) and possibly functions in the transport of
an alternative osmolyte (10). One of the ivi proteins in this
subgroup was CirA, an iron-regulated receptor for colicin ho-
mologous to a siderophore iron uptake system, which is also
expressed under iron-limiting conditions by other pathogens
such as Salmonella enterica serovar Typhimurium (16). Inter-
estingly, as in previous studies (16, 58), IVIAT identified pro-
teins expressed in response to iron limitation (FhuA and
CirA), as well as those expressed in response to extracytoplas-
mic iron excess (BasS of the BasR-BasS two-component sys-
tem; see above). Other ivi proteins included MdaA, a modu-
lator of drug activity, and two proteins that are part of the Pho
regulon and are expressed as part of the adaptive response to
limiting phosphate in the environment, namely, PhoE, an outer
membrane porin functioning in the transport of various anions,
and a periplasmic phosphate ester hydrolase, PhoA, involved
in the degradation of nontransportable organophosphates (40).
The PhoB regulon is required for colonization of the rabbit
small intestine by V. cholerae (55) and regulates hilA and in-
vasion genes in Salmonella serovar Typhimurium (31). A pos-
sible role in E. coli O157 virulence is also suggested by the fact
that in vivo expression of PhoB in an avian-pathogenic E. coli
(APEC) strain during experimental infection of chickens was
identified by SCOTS (7).
Phage-related proteins (1.11%) included an inner mem-
brane protein of unknown function and a nonspecific protease
that degrades the lambda repressor cII. Proteins of unknown
function (6.08%) rounded off ivi proteins expressed from the
backbone. Collectively, these results suggested that defined
backbone ivi proteins not only support pathogenicity by facil-
itating in vivo survival but also regulate and indirectly comple-
ment pathogen-specific virulence factors.
ivi proteins expressed from OIs. The 37 ivi proteins ex-
pressed from OIs included 13 phage-related proteins (Table
3). Because phage proteins include both Stx1 and Stx2 in
EHEC, and because they also include proteins that influence
every stage of infection of mammalian hosts by diverse patho-
gens (56), they are potential virulence factors and warrant
further evaluation. Although IVIAT did not identify either
Stx1 or Stx2 (both are also produced during in vitro growth in
LB broth) (47), it identified two homologous ivi proteins of
unknown function, one expressed from each of the phages that
encode Stx1 and Stx2. These two ivi proteins are homologous
to ivi proteins expressed from several other cryptic prophages
(Table 3).
Particularly interesting was the fact that certain OIs (OIs 36
and 71) containing cryptic prophages expressing ivi proteins
also expressed nonphage, non-LEE (Nle) effectors (proteins
encoded outside the LEE but secreted via the type III secre-
tion apparatus encoded on the LEE) (6). The presence of Nle
homologs, such as NleA and NleF (OI 71) and NleB, NleC,
and NleD (OI 36), in related pathogens and the requirement of
NleA for full virulence of Citrobacter rodentium, a pathogen of
mice, suggest a probable role for phage proteins expressed
from these OIs in E. coli O157 virulence (9).
IVIAT identified 24 clones whose inserts encoded proteins
expressed from OI sequences that are not part of phage ge-
nomes (Table 3). These included intimin-, expressed from the
LEE (OI 148); WbdP, a cytoplasmic glycosyltransferase (OI
84) involved in the synthesis of the O-polysaccharide antigen
(57); WaaD, a putative periplasmic glycosyltransferase (OI
145) involved in biosynthesis of the oligosaccharide core of
LPS; and numerous ivi proteins with putative or unknown
functions (Table 3). The identification of enzymes involved in
both O-antigen and LPS core biosynthesis by IVIAT was ex-
pected, because LPS is a broadly recognized virulence deter-
minant of pathogenic gram-negative bacteria, and transcripts
of genes encoding such enzymes were identified during infec-
tion of chickens with APEC by using SCOTS (7). Other non-
phage ivi proteins that could impact E. coli O157 virulence
included a putative arylsulfatase (OI 40) involved in the scav-
enging of sulfate and implicated in the ability of E. coli K1 to
invade brain microvascular endothelial cells (18) and a puta-
tive recombinant hot spot A (RhsA) protein (OI 30) that
reportedly contributes to genomic plasticity (30). Transcripts
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of a gene encoding RhsH, a similar protein, were also detected
during APEC infection of chickens by SCOTS (7).
Many nonphage ivi proteins were expressed from seven of
the nine large OIs (15 kb) that reportedly encode putative
virulence factors (Table 4) (44). Besides intimin- from OI
148, IVIAT also identified a putative acyl coenzyme A (CoA)
synthetase (fatty acid:CoA ligase), expressed from OI 138,
which catalyzes the formation of fatty acyl-CoA, a substrate for
phospholipid biosynthesis and enzymes of -oxidation, and is
involved in diverse functions such as protein transport, protein
acylation, enzyme activation, cell signaling, and control of tran-
scription (40); a putative inner membrane ABC-type transport
permease expressed from OI 47 and functioning in cell wall
biogenesis; a putative inner membrane ABC-type bacteriocin/

















OI 84 wbdP/glycosyltransferase/cell surface polysaccharides and antigen
synthesis
Cytoplasmic AE005429 4 0
Putative function
H-6 OI 47 Z1554/putative ABC transport, lipoprotein release, permease
component/cell wall biogenesis
Inner membrane AE005305 4 0
H-17 OI 28 Z0634/putative cytoplasmic membrane, ABC-type bacteriocin/
lantibiotic exporter/defense mechanism
Inner membrane AE005229 4 0
H-25 OI 108d Z3936/putative transposase, IS30 family Cytoplasm AE005493 4 0
H-33 OI 43 Z1214/predicted esterase of the alpha-beta hydrolase superfamily Cytoplasm AE005276 4 0
H-48, -51, -89, -90 OI 172 Z5901/putative helicase with a unique C-terminal domain including
metal-binding cysteine cluster
Cytoplasm AE005661 4 0
H-78 OI 9 Z0348/putative arabinose efflux permease/carbohydrate transport Inner membrane AE005205 2 0
H-84 OI 17 Z0419/putative ABC-type transport permease Inner membrane AE005211 4 0
H-98 OI 145 waaD/putative lipopolysaccharide biosynthesis enzyme (glycosyl-
transferase)
Periplasm AE005590 4 0
H-102 OI 138 Z4856/putative acyl-CoA synthetase/AMP-(fatty) acid ligase Inner membrane AE005571 4 0





H-129 OI 157 Z5415/predicted permease Inner membrane AE005619 2 0
H-135 OI 30 Z0705/putative RhsA/Rhs family protein Inner membrane AE005236 4 0
H-136 pO157 L7091/putative nickase Cytoplasm AF074613 4 0
H-151 OI 40 Z1089/putative arylsufatase A Cytoplasm AE005267 4 1
H-231 OI 172 Z5888/predicted transcriptional regulator Cytoplasm AE005659 4 0
H-263 OI 139 Z4882/uncharacterized protein encoded in hypervariable junctions
of pilus gene clusters
Cytoplasm AE005572 4 0
H-298 pO157 sopA/putative plasmid partitioning protein A Inner membrane AF074613 4 0
Phage related
H-18 OI 52 Z1930/putative hydrolase or acyltransferase (alpha/beta hydrolase
family), encoded within CP-933X
Inner membrane AE005334 4 1
H-38, -56 OI 52 Z1883/putative DNA-packaging protein encoded within CP-933X Cytoplasm AE005330 4 0
H-70 OI 36 Z0964/putative DNA-packaging protein encoded within CP-933K Cytoplasm AE005256 4 1
H-106 OI 45d Z1433/unknown, encoded within BP-933W Cytoplasm AE005295 4 0
H-112 OI 52 Z1882/putative phage DNA-packaging protein, NU1 subunit of
terminase, encoded in CP-933X
Cytoplasm AE005330 4 0
H-128 OI 52 Z1888/putative capsid protein of prophage CP-933X Cytoplasm AE005330 4 0
H-139 OI 57 Z2085/putative exonuclease VIII, encoded within CP-933O Cytoplasm AE005346 4 0
H-158 OI 93 Z3327/unknown, encoded within CP-933V Cytoplasm AE005441 4 0
H-191 OI 71d Z6060/putative Q anti-terminator encoded within CP-933P Cytoplasm AE006460 3 0
H-196 OI 93d Z3334/unknown, encoded within CP-933V Cytoplasm AE005442 4 1
H-247 OI 57d Z2100/unknown, encoded within CP-933O Inner membrane AE005347 4 0
H-255, -257 OI 36 Z0975/putative tail component of CP-933K Inner membrane AE005257 4 0






H-2 OI 172 Z5897/unknown Inner membrane AE005660 4 0
H-21 OI 7 Z0251/unknown (uncharacterized protein conserved in bacteria) Cytoplasm AE005198 4 0
H-107 OI 142 Z5002/unknown (uncharacterized protein conserved in bacteria) Cytoplasm AE005584 4 0
H-119 OI 89 Z3271/unknown Inner membrane AE005436 4 0
H-123 OI 89 Z3269/unknown Cytoplasm AE005436 4 0
H-146 OI 140 Z4912/unknown Cytoplasm AE005576 3 0
H-162 OI 102 Z3616/unknown Cytoplasm AE005466 4 0
H-269 OI 48d Z1606/unknown Inner membrane AE005309 4 0
a Putative functions of hypothetical proteins determined from the COGs database when available.
b Predicted by the PSORT/PSORT-B program.
c Sera from four patients with HUS and one healthy person were tested individually.
d Homologous proteins also found on other OIs.
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lantibiotic exporter expressed from OI 28 that functions in the
export of large molecules such as proteins and peptides and is
homologous to ATP-binding proteins of ABC transporters and
toxin secretion systems of several pathogens, including Pseudo-
monas putida, Salmonella enterica serovar Typhi, and V. chol-
erae; a cytoplasmic esterase of the - hydrolase superfamily
expressed from OI 43; a conserved cytoplasmic protein of
unknown function expressed from OI 7; and an inner mem-
brane protein of unknown function expressed from OI 48.
Interestingly, IVIAT did not identify clones expressing puta-
tive virulence factors encoded on OI 115 and OI 122 (Table 4).
Perhaps these proteins are expressed equally in vitro and in
vivo, resulting in the removal of corresponding reactive anti-
bodies during adsorption, or these proteins are not immuno-
genic, or antibodies to these proteins are short-lived.
ivi proteins expressed from pO157. ivi proteins expressed
from pO157 (Table 3) included the previously discussed TagA
and MsbB2; SopA, an ATPase that accurately partitions low-
copy-number F plasmids into daughter cells (also identified
during APEC infection of chickens) (7); a putative nickase
associated with plasmid maintenance; and a putative hemoly-
sin expression-modulating protein, a homolog (90% amino
acid identity) of the E. coli regulator Hha (3), which complexes
with the nucleoid-associated universal regulator protein H-NS
and governs expression of the hly operon in response to
changes in temperature and osmolarity (32). In addition, Hha
has also been shown to repress the LEE-encoded regulator
(Ler) in E. coli O157, thereby causing reduced expression of
the esp operon encoding the LEE translocator proteins EspA,
EspB, and EspD (49).
A majority of clones expressing ivi proteins reacted specif-
ically and broadly with HUS convalescent-phase serum sam-
ples from individual patients. ivi proteins for practical ap-
plications, such as the development of diagnostic markers,
vaccines, and drugs, should ideally be expressed strongly dur-
ing infection and evoke robust immune responses broadly in
patients with E. coli O157 disease. The majority of the 223
positive clones identified earlier using pooled adsorbed HUS
convalescent-phase sera reacted with each of the four individ-
ual serum samples that made up the pool but not with a control
serum sample taken from a healthy pediatric patient (Tables 1,
2, and 3). However, 15 ivi proteins expressed from the back-
bone and four ivi proteins expressed from OIs reacted differ-
entially with individual patient serum samples. We are cur-
TABLE 4. ivi proteins expressed from OIs encoding putative virulence factors
OI Putative virulence factor ivi protein/function
OI 7 Macrophage toxin and a chaperone Z0251/unknown
OI 28 An RTX-toxin-like exoprotein and transport system Z0634/putative cytoplasmic membrane ABC-type bacteriocin/lantibiotic
exporter
OI 43 Urease gene cluster Z1214/a predicted esterase
OI 47 Adhesin and polyketide or fatty acid biosynthesis system Z1554/putative ABC-type transporter
OI 48 Urease gene cluster Z1606/unknown
OI 115 TTSSa and secreted proteins similar to Samonella-Shigella
Inv-Spa host cell invasion proteins
None identified
OI 122 Two toxins and a PagC-like virulence factor None identified
OI 138 Fatty acid biosynthesis system Z4856/putative acyl-CoA synthetase/fatty acid ligase
OI 148 LEE proteins Eae/-intimin/attaching and effacing
a TTSS, type III secretion system.
TABLE 5. O157 backbone ivi proteins expressed in vitro as identified by proteomic analysis
Protein no. O157 ivi protein





Run 1 Run 2
1 Z4279 transketolase 1 isozyme (tktA)   0.49
2 Z5747 GroES, 10-kDa chaperone binds to Hsp60 (mopB)   0.32
3 Z4263 fructose-bisphosphate aldolase, class II (fba)   0.28
4 Z4540 degrades sigma 32, integral membrane peptidase, cell division (hflB)   0.17
5 Z4616 acetyl-CoA carboxylase, biotin carboxylase subunit (accC)   0.14
6 Z4228 lysine tRNA synthetase, constitutive suppressor of ColE1 (lysS)   0.13
7 Z0176 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase (dapD)   0.11
8 Z3999 alanyl-tRNA synthetase (alaS)   0.11
9 Z2789 putative thiosulfate sulfur transferase   0.10
10 Z3827 serine hydroxymethyltransferase (glyA)   0.09
11 Z5977 hyperosmotically inducible periplasmic protein (osmY)   0.08
12 Z3777 histidine tRNA synthetase (hisS)   0.07
13 Z5955 methyl-accepting chemotaxis protein I, serine sensor receptor (tsr)   0.06
14 Z3491 ribonucleoside diphosphate reductase 1, beta subunit, B2 (nrdB)   0.06
15 Z4043 methyl-directed mismatch repair (mutS)   0.05
16 Z4478 ORF, hypothetical protein (yhaF)   0.05
17 Z0998 DNA repair excision nuclease subunit B (uvrB)   0.05
18 Z5392 protein disulfide isomerase I, essential for cytochrome (dsbA)   0.04
a Two 4-h runs were done using this denaturing condition. Each yielded more than 300 proteins.
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rently investigating via PCR whether the failure of individual
patients to respond to a particular ivi protein is attributable to
heterogeneity of cognate isolates. Also, 22 backbone (Table 2)
and 2 E. coli O157-specific (Table 3) ivi proteins reacted with
the control serum. We speculate that this may be due to cross-
reacting antibodies in the control sera or to the presence of
preexisting antibodies to O157 proteins from prior, unrecog-
nized infection. Studies are ongoing to compare the reactivities
of sera from healthy individuals of different age groups to the
ivi antigens.
ivi proteins expressed from OIs and pO157 were not among
the 300 O157 proteins most highly expressed during in vitro
growth. The central premise of IVIAT is that the proteins
identified are expressed specifically during infection but not
FIG. 3. Graphical representation of the locations of ivi genes on the chromosome of E. coli O157 strain EDL933. Outer and inner circles show
the positions of ivi genes on the backbone and OIs, respectively. The black numbers on the outside of the inner circle refer to individual OIs (44).
Individual OI genes, phage-associated genes, the LEE (encoding intimin-), CP-933V (encoding Stx1), and BP-933W (encoding Stx2) are also
shown. OI groups, I, II, and III are indicated (see the text). The innermost circle shows the scale in base pairs. This figure was created using
Genvision software from DNASTAR.
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during growth under standard laboratory conditions. Proteo-
mic analysis using ESILC-MS/MS confirmed that none of the
37 ivi proteins expressed from OIs and none of the 5 expressed
from pO157 were among the 300 O157 proteins most highly
expressed during growth in LB broth (data not shown). This
was not entirely expected, because some of the E. coli O157-
specific proteins are reportedly expressed, at least to some
degree, in vitro (36). We speculate that, owing to low-level
expression of such proteins during in vitro culture, an MS run
of longer duration would be required for their identification.
In contrast, 18 of 181 backbone ivi proteins were expressed
sufficiently in LB broth for detection by proteomic analysis
(Table 5). Of these 18 backbone ivi proteins expressed in vitro,
12 were identified by ESILC-MS/MS during the course of
both runs; 6 of which were weakly expressed at a percent
protein abundance ranging from 0.09 to 0.04%, and the re-
maining 6 were expressed in only one run (Table 5). We hy-
pothesize that these 18 proteins are expressed at higher levels
during human infection than during growth in LB broth and
attribute their identification by IVIAT to the fact that low-level
protein expression during in vitro growth may not effectively
deplete HUS convalescent-phase sera of antibodies against
these ivi proteins during absorption.
Graphical representations of the locations of ivi genes on the
E. coli O157 chromosome and on the pO157 plasmid are
shown in Fig. 3 and 4, respectively. ivi genes included 181 of
4,029 (4.5%) open reading frames (ORFs) in the backbone, 37
of 1,387 (2.7%) ORFs in the OIs, and 5 of 100 (5%) ORFs in
pO157 sequences of the EDL933 genome (44).
The 181 backbone-specific ivi genes were distributed uni-
formly on the E. coli O157 chromosome; however, several of
the 37 OI-specific ivi genes appeared to localize in three dis-
crete OI groups (a group contained four or more OIs, with
each separated by five or fewer intervening OIs). Although
in most cases only one ivi gene mapped to an individual OI,
there were instances where multiple ivi genes (two or more)
mapped within the same OI (OI 36, OI 52, OI 57, OI 89, OI
93). The five ivi genes that mapped to pO157 are also shown
in Fig. 4.
The apparent grouping of OIs expressing ivi proteins raises
the possibility that ivi proteins (and other proteins) expressed
from OIs within a particular group might act in concert to
optimally influence a specific function. Particularly interesting
was the fact that group I, which included OI 148, expressing the
adhesin intimin-, also included OI 145, expressing the glyco-
syltransferase WaaD, one of the many enzymes involved in the
biosynthesis of LPS core oligosaccharide. The facts that WaaD
is expressed from the same operon as WaaI (another enzyme
that functions in LPS core oligosaccharide biosynthesis) and
that E. coli O157 waaI deletion mutants are hyperadherent to
cultured intestinal epithelial cells (54) may suggest that during
human infection, intimin- and E. coli O157 LPS (and possibly
other ivi and non-ivi proteins, expressed from OIs within this
group) might act in concert to modulate the adherence of
E. coli O157 to human epithelial cells. It will be interesting to
test this hypothesis experimentally and also to determine
whether proteins in OI groups II and III might be functionally
related as well.
In conclusion, IVIAT identified 223 O157 proteins ex-
pressed in vivo during human infection, several of which were
unique to this study. Judged by our results, IVIAT enables
identification both of proteins expressed specifically during
human infection but not during growth under standard labo-
ratory conditions and of proteins expressed at significantly
higher levels in vivo than in vitro. Although IVIAT for E. coli
O157 was validated by the identification of previously identi-
fied potential E. coli O157 virulence factors, prior infection
with E. coli O157 does not necessarily produce full protection
from subsequent reinfection (1). This may reflect suboptimal
antibody responses to protective antigens, and we hypothesize
that robust expression and optimal delivery of relevant ivi
proteins (and other O157 antigens) to the mucosal immune
system might engender more-protective immune responses.
Preliminary experiments demonstrated that all of the 223 re-
active clones also reacted with pooled adsorbed sera from
patients who had recovered from hemorrhagic colitis (data not
shown), suggesting that similar pathogenic mechanisms may be
operating in this illness and HUS.
IVIAT provides a “snapshot” of O157 protein expression
during infection and a glimpse of the possible mechanisms by
which this pathogen might counter host defenses and adapt
and establish itself within the human gut to cause disease.
Studies directed toward the characterization of the role of ivi
proteins in E. coli O157 pathogenesis are currently under way.
The identification of ivi genes unique to diverse E. coli O157
isolates, as well as identification of those unique to non-O157
EHEC or to Shiga-toxigenic E. coli (STEC), which lacks LEE
but is pathogenic to humans, and of ivi genes shared between
EHEC and EPEC (unpublished data), augurs well for the
future development of diagnostic tests for EHEC and STEC
infection, as well as for the development of common drugs and
vaccines against EHEC, STEC, and EPEC.
FIG. 4. Graphical representation of the locations of ivi genes on
the pO157 plasmid of E. coli O157 strain EDL933. The outer circle
shows the positions of ivi genes (magenta), and the inner circle, the
scale in base pairs. This figure was created using Genvision software
from DNASTAR.
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